GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.
Ticker SymbolWGSWW
Company nameGeneDx Holdings Corp
IPO dateSep 04, 2020
CEOMs. Katherine A. Stueland
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address333 Ludlow Street
CitySTAMFORD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06902
Phone18887291206
Websitehttps://sema4.com/
Ticker SymbolWGSWW
IPO dateSep 04, 2020
CEOMs. Katherine A. Stueland
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data